sults to differ
materially. These risks and uncertainties include, but are not limited to,
our compliance with the Deferred Prosecution Agreement through March 2009
and the Corporate Integrity Agreement through 2012, the impact of our
enhanced healthcare compliance global initiatives and business practices on
our relationships with customers and consultants, our market share and our
overall financial performance, the success of our quality initiatives, the
outcome of the informal investigation by the U.S. Securities and Exchange
Commission into Foreign Corrupt Practices Act matters announced in October
2007, price and product competition, rapid technological development,
demographic changes, dependence on new product development, the mix of our
products and services, supply and prices of raw materials and products,
customer demand for our products and services, control of costs and
expenses, our ability to obtain and maintain adequate intellectual property
protection, our ability to successfully integrate acquired businesses, our
ability to form and implement alliances, international growth, our
compliance with governmental laws and regulations affecting our U.S. and
international businesses including regulations of the U.S. Food and Drug
Administration and foreign government regulators and tax obligations and
risks, product liability and intellectual property litigation losses,
reimbursement levels from third-party payors, cost-containment efforts of
healthcare purchasing organizations, our ability to retain the independent
agents and distributors who market our products, general industry and
market conditions and growth rates and general domestic and international
economic conditions including interest rate and currency exchange rate
fluctuations. For a further list and description of such risks and
uncertainties, see our periodic reports filed with the U.S. Securities and
Exchange Commission. We disclaim any intention or obligation to update or
revise any forward
'/>"/>SOURCE Zimmer Holdings, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related medicine news :1.
Zimmer Holdings Offer and ORTHOsoft Directors Circular Mailed to Shareholders2.
Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2007 Results3.
Zimmer Announces Successful Completion of ORTHOsoft Takeover Bid4.
Zimmer Holdings to Present at Upcoming Investor Conferences5.
Ray Elliott to Retire as Chairman of Zimmer Holdings; John McGoldrick to Serve as Non-Executive Chairman6.
Zimmer Holdings Receives FDA Approval to Market Mobile Bearing Knee7.
Zimmer Holdings to Present at JPMorgan Healthcare Conference8.
Zimmer Holdings Announces Webcast and Conference Call of Fourth Quarter and Full-Year 2007 Results9.
Zimmer Spine Introduces New Rigid to Dynamic Stabilization Transition System10.
Zimmer Reports Fourth Quarter and 2007 Financial Results11.
Zimmer Holdings to Present at Merrill Lynch Health Care Conference